Clinical Trials Logo

Oesophageal Adenocarcinoma clinical trials

View clinical trials related to Oesophageal Adenocarcinoma.

Filter by:
  • Suspended  
  • Page 1

NCT ID: NCT05135845 Suspended - Clinical trials for Gastric Adenocarcinoma

Combination of Capmatinib + Spartalizumab in Advanced Oesogastric Adenocarcinoma

METIMGAST
Start date: March 22, 2022
Phase: Phase 2
Study type: Interventional

Immunotherapy with anti-PD1 antibodies provides encouraging results on a subset of patients. Capmatinib, a MET inhibitor, has shown an imunomodulatory effect and a synergy with spartalizumab a PD-1 inhibitor. The purpose of this phase II trial is to evaluate the efficacy and safety of the combination of capmatinib + spartalizumab in adult patients with advanced oesogastric adenocarcinoma.